| 韩松甫,卫利民,梁仁杰,等.三阴性乳腺癌新辅助治疗方案疗效的信息论网状荟萃分析[J].肿瘤学杂志,2025,31(11):959-972. |
| 三阴性乳腺癌新辅助治疗方案疗效的信息论网状荟萃分析 |
| An Information-Theoretic Network Meta-Analysis of Efficacy of Neoadjuvant Treatment Regimens for Triple-Negative Breast Cancer |
| 投稿时间：2024-12-09 |
| DOI：10.11735/j.issn.1671-170X.2025.11.B006 |
|
 |
| 中文关键词: 三阴性乳腺癌 新辅助治疗 信息论网状荟萃分析 |
| 英文关键词:triple-negative breast cancer neoadjuvant treatment information-theoretic network meta-analysis |
| 基金项目: |
|
| 摘要点击次数: 6 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘 要：［目的］ 采用信息论网状荟萃分析方法比较三阴性乳腺癌（triple-negative breast cancer，TNBC）新辅助治疗方案的有效性。［方法］ 检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、万方和维普数据库，搜集TNBC新辅助治疗的随机对照试验，研究者按照纳入和排除标准进行文献筛选、数据提取，并进行偏倚风险的评估；采用RStudio 4.3.0和Revman 5.4统计软件，采用信息论网状荟萃分析方法分析各种新辅助治疗方案的得分。［结果］ 纳入42篇文献共计9 708例TNBC患者，涉及49种新辅助治疗方案。信息论网状荟萃分析结果显示，TNBC新辅助治疗方案病理完全缓解率前3名方案为：紫杉+蒽环+铂类，紫杉+铂类，紫杉+免疫检查点抑制剂序贯蒽环联合环磷酰胺，其对应的得分依次为12.69、7.76、6.76。亚组分析显示铂类能够提高TNBC患者的病理完全缓解率（RR=1.57，95%CI:1.32~1.87，P＜0.001）；免疫检查点抑制剂能够提高TNBC患者的病理完全缓解率（RR=1.36，95%CI:1.16~1.60，P＜0.001）。［结论］ 在TNBC新辅助治疗方案中，紫杉联合蒽环及铂类方案的病理完全缓解率最佳，但临床应用中仍需综合患者实际及药物相关毒副作用进行个体化方案治疗。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the efficacy of neoadjuvant regimens for triple-negative breast cancer (TNBC) with information-theoretic network meta-analysis.［Methods］ PubMed， Embase， Cochrane Library， Web of Science， CNKI， Wanfang and VIP databases were searched to collect randomized controlled trial (RCT) of TNBC neoadjuvant therapy. Literature screening， data extraction， and risk-of-bias assessment were performed according to predefined inclusion and exclusion criteria. Statistical analysis was performed using RStudio 4.3.0 and Revman 5.4. The scores of neoadjuvant treatment regimens were analyzed using information-theoretic network meta-analysis. ［Results］ A total of 42 RCT involving 9 708 TNBC patients and 49 neoadjuvant regimens were included. The top 3 regimens in terms of pathologic complete response (pCR) rates were paclitaxel + anthracycline + platinum (score: 12.69)， paclitaxel + platinum (score： 7.76)， and paclitaxel + immune checkpoint inhibitor followed by anthracycline + cyclophosphamide (score： 6.76). Subgroup analysis showed that platinum-based chemotherapy increased the pathologic complete response (pCR) rate of TNBC patients(RR=1.57， 95%CI：1.32~1.87， P<0.001). The immune checkpoint inhibitors increased the pCR rate of TNBC patients(RR=1.36， 95%CI：1.16~1.60， P<0.001). ［Conclusion］ Among the neoadjuvant regimens for TNBC， paclitaxel plus anthracycline plus platinum regimen achieved the best pCR rate. However， individualized treatment planning should also consider patient-specific factors and treatment-related toxicities. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |